CGON
CG Oncology, Inc. Common stock
NASDAQ · USHealthcareBiotechnology
$70.19-2.31%
Price as of Jul 20, 2026
CGON growth
CG Oncology, Inc. Common stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +666.0%
- EBITDA
- -45.7%
- EBIT
- -59.9%
- EPS
- -53.9%
- Free cash flow
- -95.1%
- Operating cash flow
- -95.2%
Forward estimates
- Revenue
- +976.1%
- EBITDA
- +70.4%
- EPS
- -30.1%
Three-year CAGR
- Revenue
- +176.6%
- EBITDA
- -81.3%
- EBIT
- -66.4%
- Net income
- -82.9%
- EPS
- -47.5%
- Free cash flow
- -67.8%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.